Influence of different tropical fruits on biological and behavioral aspects of the Mediterranean fruit fly Ceratitis capitata (Wiedemann) (Diptera, Tephritidae)

Influence of different tropical fruits on biological and behavioral aspects of the Mediterranean fruit fly Ceratitis capitata (Wiedemann) (Diptera, Tephritidae). Studies on Ceratitis capitata, a world fruit pest, can aid the implementation of control programs by determining the plants with higher vulnerability to attacks and plants able to sustain their population in areas of fly distribution. The objective of the present study was to evaluate the influence of eight tropical fruits on the following biological and behavioral parameters of C. capitata: emergence percentage, life cycle duration, adult size, egg production, longevity, fecundity, egg viability, and oviposition acceptance. The fruits tested were: acerola (Malpighia glabra L.), cashew (Anacardium occidentale L.), star fruit (Averrhoa carambola L.), guava (Psidium guajava L.), soursop (Annona muricata L.), yellow mombin (Spondias mombin L.), Malay apple (Syzygium malaccense L.), and umbu (Spondias tuberosa L.). The biological parameters were obtained by rearing the recently hatched larvae on each of the fruit kinds. Acceptance of fruits for oviposition experiment was assessed using no-choice tests, as couples were exposed to two pieces of the same fruit. The best performances were obtained with guava, soursop, and star fruit. Larvae reared on cashew and acerola fruits had regular performances. No adults emerged from yellow mombin, Malay apple, or umbu. Fruit species did not affect adult longevity, female fecundity, or egg viability. Guava, soursop, and acerola were preferred for oviposition, followed by star fruit, Malay apple, cashew, and yellow mombin. Oviposition did not occur on umbu. In general, fruits with better larval development were also more accepted for oviposition.

Espécies de Gorybia Pascoe (Coleoptera, Cerambycidae, Piezocerini) ocorrentes na Bolívia

Species of Gorybia Pascoe (Coleoptera, Cerambycidae, Piezocerini) occurring in Bolivia. The genus Gorybia (Cerambycinae, Piezocerini) consists of 45 described species with seven species recorded from Bolivia. Nine new species are described herein from Bolivia: G. abnormalis sp. nov.; G. alveolata sp. nov.; G. asyka sp. nov.; G. florida sp. nov.; G. inarmata sp. nov.; G. longithorax sp. nov.; G. guenda sp. nov.; G. tuberosa sp. nov. and G. wappesi sp. nov. A key to the species now known to occur in Bolivia is included.

Influence of tree species on the herbaceous understory and soil chemical characteristics in a silvopastoral system in semi-arid northeastern Brazil

Studies from some semi-arid regions of the world have shown the beneficial effect of trees in silvopastoral systems, by promoting the formation of resource islands and increasing the sustainability of the system. No data are available in this respect for tree species of common occurrence in semi-arid Northeastern Brazil. In the present study, conducted in the summer of 1996, three tree species (Zyziphus joazeiro, Spondias tuberosa and Prosopis juliflora: ) found within Cenchrus ciliaris pastures were selected to evaluate differences on herbaceous understory and soil chemical characteristics between samples taken under the tree canopy and in open grass areas. Transects extending from the tree trunk to open grass areas were established, and soil (0-15 cm) and herbaceous understory (standing live biomass in 1 m² plots) samples were taken at 0, 25, 50, 100, 150 and 200% of the average canopy radius (average radius was 6.6 ± 0.5, 4.5 ± 0.5, and 5.3 ± 0.8 m for Z. joazeiro, P. juliflora, and S. tuberosa , respectively). Higher levels of soil C, N, P, Ca, Mg, K, and Na were found under the canopies of Z. joazeiro and P. juliflora: trees, as compared to open grass areas. Only soil Mg organic P were higher under the canopies of S. tuberosa trees, as compared to open grass areas. Herbaceous understory biomass was significantly lower under the canopy of S. tuberosa and P. juliflora trees (107 and 96 g m-2, respectively) relatively to open grass areas (145 and 194 g m-2). No herbaceous biomass differences were found between Z. joazeiro canopies and open grass areas (107 and 87 g m-2, respectively). Among the three tree species studied, Z. joazeiro was the one that presented the greatest potential for use in a silvopastoral system at the study site, since it had a larger nutrient stock in the soil without negatively affecting herbaceous understory biomass, relatively to open grass areas.

Adição de níquel na solução nutritiva para o cultivo de mudas de umbuzeiro

Com o objetivo de avaliar a influência da adição de Ni na solução nutritiva de Hoagland & Arnon sobre o crescimento e a nutrição mineral de mudas de umbuzeiro, realizou-se este trabalho. O delineamento experimental utilizado foi o inteiramente casualizado, com quatro repetições e seis doses de Ni (0; 0,0005; 0,05; 0,1; 0,5 e 1,0 mmol L-1). Observou-se que o Ni, em pequenas concentrações, estimula o crescimento de mudas de umbuzeiro em solução nutritiva; para o cultivo destas em solução nutritiva de Hoagland & Arnon, recomenda-se a adição de 0,03 mmol L-1 de Ni.

Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

Background Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central nervous system (CNS) and is the leading cause of nontraumatic disability among young adults. Activated microglial cells are important effectors of demyelination and neurodegeneration, by secreting cytokines and others neurotoxic agents. Previous studies have demonstrated that microglia expresses ATP-sensitive potassium (KATP) channels and its pharmacological activation can provide neuroprotective and anti-inflammatory effects. In this study, we have examined the effect of oral administration of KATP channel opener diazoxide on induced experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Methods Anti-inflammatory effects of diazoxide were studied on lipopolysaccharide (LPS) and interferon gamma (IFNy)-activated microglial cells. EAE was induced in C57BL/6J mice by immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55). Mice were orally treated daily with diazoxide or vehicle for 15 days from the day of EAE symptom onset. Treatment starting at the same time as immunization was also assayed. Clinical signs of EAE were monitored and histological studies were performed to analyze tissue damage, demyelination, glial reactivity, axonal loss, neuronal preservation and lymphocyte infiltration. Results Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-¿) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis. Oral treatment of mice with diazoxide ameliorated EAE clinical signs but did not prevent disease. Histological analysis demonstrated that diazoxide elicited a significant reduction in myelin and axonal loss accompanied by a decrease in glial activation and neuronal damage. Diazoxide did not affect the number of infiltrating lymphocytes positive for CD3 and CD20 in the spinal cord. Conclusion Taken together, these results demonstrate novel actions of diazoxide as an anti-inflammatory agent, which might contribute to its beneficial effects on EAE through neuroprotection. Treatment with this widely used and well-tolerated drug may be a useful therapeutic intervention in ameliorating MS disease.

Calbindin D-28K and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis

The morphology and distribution of local-circuit neurons (interneurons) were examined, by calbindin D-28k and parvalbumin immunocytochemistry, in the frontal cortex (area 8) in two patients with frontal lobe dementia of non-Alzheimer type associated with classical amyotrophic lateral sclerosis (ALS), and in seven normal cases. The density of calbindin D-28k immunoreactive cells was dramatically reduced in ALS patients, but the density of parvalbumin-immunoreactive neurons was preserved. Decreased density of calbindin D-28k-immunoreactive neurons, which are mainly located in the upper cortical layers, may interfere with the normal processing of cortico-cortical connections, whereas integrity of parvalbumin-immunoreactive cells may be associated with the preservation of the major inhibitory intracortical circuits in patients with frontal lobe dementia.

Notas nomenclaturales, taxonomicas y corologicas sobre el género Cuphea (Lythraceae) en el Paraguay.

Se presenta el tratamiento nomenclatural del genero Cuphea (Lythraceae) en el Paraguay, que reúne el nombre correcto para las 28 especies reconocidas y su correspondiente sinonimia. Para la mayoría de taxones que se mencionan en el texto se ha revisado su tipificación. Se tipifican por primera vez el subgénero Lytrocuphea Koehne y las secciones Brachyandra Koehne y Enatiocuphea Koehne y se lectotipifican C. tuberosa Cham. & Schltdl., C. inaequalifolia Koehne. C. punctulata Koehne, además de varios sinónimos. Se proponen las siguientes combinaciones nomenclaturales: C. corisperma subsp. hexasperma (Koehne) Duré & Molero. C. racemosa subsp. longiflora (Koehne) Duré & Molero y C. racemosa var. ramosior (Koehne ) Duré & Molero. Desde el punto de vista corológico se citan por primera vez para el Paraguay C. micrahtha Humb., Bonpl. & Kunth. Cuphea rusbyi Lourteig y C. sessilifoila Mart. Se incluyen también algunos comentarios taxonómicos sobre táxones críticos como C. corisperma Koehne, C. hassleri Koehne y C. racemosa (L. f.) Sprengel , entre otros.

Neutralizing antibodies in Multiple Sclerosis a model-based analysis of Interferon beta signaling pathway in macrophages

Multiple Sclerosis is the most common non-traumatic cause of neurologicaldisability in young people. There is no cure yet, and until recently, few long-termtherapies existed. Interferon beta (IFNβ) was the first treatment, and remains the mostcommonly prescribed. One of the most significant problems of IFNβ therapy is theproduction of drug specific antibodies. Up to 45% of patients develop neutralizingantibodies (NAbs) to IFNβ products. The neutralizing antibody binds to the biologicalagent preventing its interaction with its receptor, inhibiting the biological action of theprotein, which abrogates the clinical efficacy of IFNβ treatment. Interferon-betamediates its response by binding to its high affinity cell surface receptor and initiatingthe JAK/STAT signalling cascade. In this project we have analyzed the IFNβ signalingpathway in macrophages when neutralizing antibodies are present. The response tothis pathway after IFNβ stimulation shows a transient oscillatory rhythm of STAT1phosphorylation, which varies as NAbs concentration increases. To improve ourunderstanding of that behavior, we extended an existing mathematical model based onnonlinear ordinary differential equations of JAK/STAT pathway by including IFN-NAbassociation and IFN-activation receptor. Combining our theoretical model withexperimental data we could study the role of neutralizing antibodies on the molecularresponse and determine its lifetime after cytokine stimulation.

Deficiência nutricional em mudas de umbuzeiro decorrente da omissão de macronutrientes

O objetivo deste trabalho foi avaliar o crescimento e os sintomas visuais de deficiência de macronutrientes em mudas de umbuzeiro, Spondias tuberosa, cultivadas em solução nutritiva completa e com omissão individual de N, P, K, Ca, Mg e S. As ausências de Ca, N, Mg e K provocaram redução do crescimento das mudas. A omissão de macronutrientes provocou alterações morfológicas características da deficiência nutricional. Observa-se maior exigência em N, K, Ca e Mg na fase inicial de crescimento e a redução na massa de matéria seca total segue a ordem: Ca > N > K > Mg > S > P.

The psychosocial difficulties in brain disorders that explain short term changes in health outcomes.

BACKGROUND: This study identifies a set of psychosocial difficulties that are associated with short term changes in health outcomes across a heterogeneous set of brain disorders, neurological and psychiatric. METHODS: Longitudinal observational study over approximately 12 weeks with three time points of assessment and 741 patients with depression, bipolar disorders, multiple sclerosis, parkinson's disease, migraine, traumatic brain injury and stroke. The data on disability was collected with the checklist of the International Classification of Functioning, Disability and Health. The selected health outcomes were the Short Form 36 and the World Health Organization Disability Assessment Schedule. Multilevel models for change were applied controlling for age, gender and disease severity. RESULTS: The psychosocial difficulties that explain the variability and change over time of the selected health outcomes were energy and drive, sleep, and emotional functions, and a broad range of activities and participation domains, such as solving problems, conversation, areas of mobility and self-care, relationships, community life and recreation and leisure. CONCLUSIONS: Our findings are of interest to researchers and clinicians for interventions and health systems planning as they show that in addition to difficulties that are diagnostic criteria of these disorders, there are other difficulties that explain small changes in health outcomes over short periods of time.

Características de doce em massa de umbu verde e maduro e aceitação pelos consumidores

O objetivo deste trabalho foi avaliar formulações de doces, em massa de umbu verde e maduro, quanto às características físico-químicas e físicas, e quanto à aceitação pelos consumidores residentes no Rio de Janeiro. Quatro formulações de doces foram processadas para polpa de umbu verde: F1, 0,3% de goma xantana; F2, 5% de xarope de glicose e 0,3% de goma xantana; F3, 0,5% de amido modificado; F4, 5% de xarope de glicose e 0,5% de amido modificado; e quatro formulações para polpa de umbu maduro: F1, apenas correção de pH; F2, 0,5% de pectina; F3, 0,3% de goma xantana; F4, 5% de xarope de glicose e 0,5% de amido modificado. Foram avaliadas as seguintes características físico-químicas e físicas: sólidos solúveis, acidez titulável, pH, açúcares redutores e não redutores, atividade de água, cor, firmeza e adesividade. Cinqüenta e seis consumidores avaliaram as formulações, por meio de escala hedônica estruturada de nove pontos. As formulações F2 apresentaram maior firmeza. Os consumidores atribuíram notas superiores a seis na escala utilizada, para todas as formulações, o que indica aceitação dos produtos.

Programa de atención a pacientes con Esclerosis Lateral Amiotrófica (ELA): Información para el personal sanitario de los Centros de Atención Primaria

Etimológicamente, esclerosis significa endurecimiento (skerós es "endurecmiento patológico" y osis, "enfermedad") y hace referencia al estado de la médula espinal en las fases avanzadas de la enfermedad. Lateral significa "al lado" y pone de manifiesto la ubicación del daño en la médula espinal. Por último, el término amiotrófica significa "sin nutrición muscular" y se refiere a la pérdida de señales que los nervios envían normalmente a los músculos. La Esclerosis Lateral Amiotrófica (ELA) es la enfermedad más grave de un grupo de dolencias que tienen síntomas similares y son conocidas como "enfermedades de motoneuronas": la Atrofia Muscular Juvenil o Enfermedad de Kugelberg Welander, la Atrofia Muscular Infantil o Enfermedad de Werdnig Hoffmann, la parálisis bulbar progresiva, la amiotrofia focal benigna, la esclerosis lateral primaria y la atrofia muscular espinobulbar o Enfermedad de Kennedy.

Variabilidade genética do umbuzeiro no Semi-Árido brasileiro, por meio de marcadores AFLP

O objetivo deste trabalho foi avaliar a distribuição da variabilidade genética do umbuzeiro (Spondias tuberosa), no Semi-Árido brasileiro, por meio de marcadores AFLP, para subsidiar estratégias de prospecção e conservação da espécie. Foram analisados 68 indivíduos de umbuzeiro de 15 ecorregiões, pelo dendrograma UPGMA e pela dispersão em escala multidimensional (MDS), com o coeficiente de Jaccard de 141 bandas polimórficas de AFLP. A análise da variância molecular foi realizada pela decomposição total entre e dentro das regiões ecogeográficas. O dendrograma apresentou valor cofenético de 0,96, e o gráfico MDS apresentou 0,25 para a falta de ajustamento. A variabilidade genética do umbuzeiro foi estimada em 0,3138, o que indica grande variação entre os grupos de indivíduos. Agrupamentos específicos foram observados em seis regiões ecogeográficas, enquanto nas demais regiões observaram-se pares entre alguns indivíduos, sem formação de agrupamentos específicos por local de amostragem, o que indica que a variabilidade genética do umbuzeironão está uniformemente distribuída no Semi-Árido. Sugerem-se estratégias para o estabelecimento de maior número de áreas para conservação in situ ou amostragens de menor número de indivíduos, em várias unidades de paisagens, para conservação ex situ da variabilidade genética do umbuzeiro.

Natalizumab versus Interferon B-1b to prevent CDMS in patients with CIS and poor prognostic factors: research protocol

About 85% of multiple sclerosis (MS) cases start as clinically isolated syndrome (CIS).When patients present with a CIS, clinicians face with many questions, most of themrelated with prognosis and treatment. Thereby, patients with CIS have been focus ofresearch. Several studies have demonstrated a relationship between positive IgM lipidspecific oligoclonal band pattern in CSF and higher lesion load on MRI brain scan, higher number of relapses and greater disability, even at the first stages of the disease. On the other hand, no studies have used this previous evidence to treat with more aggressive disease modifying therapy in initial stages of disease course to prevent the earlier axonal damage. The aim of this study is to assess the most effective approved treatment for MS and current therapy for CIS patients presenting high risk to develop CDMS and with biomarkers of poor prognosis. Among this group of patients any disease activity will eventually lead to disability. Therefore, the earlier the treatment is initiated, the more effective to prevent disability will be. It is considered that “time lost is brain lost” and since once damage is established, there is no therapy to be regained later on. In this phase III clinical trial, 172 patients will be randomized 1:1 to receive Interferon β-1b or natalizumab over 96 weeks. Time to develop clinical definitive multiple sclerosis (CDMS) will be included as primary endpoint. Other secondary endpoints will include clinical data, magnetic resonance imaging (MRI) measurements and quality of life tests

Natalizumab versus Interferon B-1b to prevent CDMS in patients with CIS and poor prognostic factors: research protocol

About 85% of multiple sclerosis (MS) cases start as clinically isolated syndrome (CIS).When patients present with a CIS, clinicians face with many questions, most of themrelated with prognosis and treatment. Thereby, patients with CIS have been focus ofresearch. Several studies have demonstrated a relationship between positive IgM lipidspecific oligoclonal band pattern in CSF and higher lesion load on MRI brain scan, higher number of relapses and greater disability, even at the first stages of the disease. On the other hand, no studies have used this previous evidence to treat with more aggressive disease modifying therapy in initial stages of disease course to prevent the earlier axonal damage. The aim of this study is to assess the most effective approved treatment for MS and current therapy for CIS patients presenting high risk to develop CDMS and with biomarkers of poor prognosis. Among this group of patients any disease activity will eventually lead to disability. Therefore, the earlier the treatment is initiated, the more effective to prevent disability will be. It is considered that “time lost is brain lost” and since once damage is established, there is no therapy to be regained later on. In this phase III clinical trial, 172 patients will be randomized 1:1 to receive Interferon β-1b or natalizumab over 96 weeks. Time to develop clinical definitive multiple sclerosis (CDMS) will be included as primary endpoint. Other secondary endpoints will include clinical data, magnetic resonance imaging (MRI) measurements and quality of life tests